阿立哌唑治疗22例迟发性运动障碍的临床研究

目的：观察阿立哌唑治疗精神分裂症患者迟发性运动障碍（TD）的临床疗效和不良反应.方法：对22例患有迟发性运动障碍的精神分裂症患者在原有药物不变的情况下,加用小剂量阿立哌唑治疗,观察周期12周.22例患者治疗前和治疗第4、8、12周采用异常不自主运动量表（AIMS）评定TD疗效,采用治疗中需处理的不良反应症状量表（TESS）评定不良反应.结果：加用小剂量阿立哌唑前后自身对照比较：AIMS总分较治疗前显著降低,差异有统计学意义（P＜0.05）;随着TD的好转,治疗第4周末,TESS总分开始下降,直到12周末,有统计学意义（P＜0.05）.结论：加用小剂量阿立哌唑治疗TD有效,用药方便、不良反应少且安全可靠,值得在临床上推广应用.

Clinical study of aripirazole in treatment of twenty-two inpatients with tardive dyskinesia

ObjectiveTo explore effectiveness and side effects of aripiprazole in treatment of tardive dyskinesia （TD） forschizophrenic inpatients. Methods：Twenty-two inpatients who met with the criteria for schizophrenic （CCMC-3） and tardive dyskine-sia （TD） were treated with low dose of aripiprazole based on the original drug for 12 weeks. Before and 4, 8, and 12 weeks after thetreatment, the effectiveness was assessed by abnormal involuntary movement scale （AIMS）, and the side effects were evaluated bytreatment emergent symptoms scale （TESS）. Results： After the treatment, the AIMS score obviously decreased, and the difference be-fore and after the treatment was statistically significant （P〈0. 05）. With the improvement of TD, TESS score began to decrease 4weeks after the treatment and this trend lasted until 12 weeks after the treatment, and the difference was statistically significant （P〈0.05）. Conclusions： Low dose aripiprazole is effective, convenient, and safe in the treatment of the schizophrenic inpatients with TDwith less side effects, and is worthy of popularization in the clinical fields.